Image

Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market – Industry Trends and Forecast to 2029

Healthcare

Image

Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Published Report
  • Aug 2022
  • MEA
  • 350 Pages
  • No of Tables: 99
  • No of Figures: 43

Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market, By Application (Novel Drug Candidates, Drug Optimization and Repurposing Preclinical Testing and Approval, Drug Monitoring, Finding New Diseases Associated Targets and Pathways, Understanding Disease Mechanisms, Aggregating and Synthesizing Information, Formation & Qualification of Hypotheses, De Novo Drug Design, Finding Drug Targets of an Old Drug and Others), Technology (Machine Learning, Deep Learning, Natural Language Processing and Others), Drug Type (Small Molecule and Large Molecule), Offering (Software and Services), Indication (Immuno-Oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases and Others), End Use (Contract Research Organizations (CROs), Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes and Others) Industry Trends and Forecast to 2029.

Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market

Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market Analysis and Insights  

Artificial Intelligence (AI) is expected to be a lucrative technology in the healthcare industry. The implementation of AI reduces R&D gap in the drug manufacturing process and helps in targeted manufacturing of drug. Hence, biopharmaceutical companies are turning to AI to enhance their market share. AI for drug discovery is a technology that uses machines to simulate human intelligence to solve complicated challenges in the drug development procedure.

Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market

Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market

The adoption of AI solutions in the clinical trial process eliminates possible obstacles, reduces clinical trial cycle time, and increases the productivity and accuracy of the clinical trial process. Technological advancements in AI for drug discovery and reduction in total time involved in drug discovery process are other factors driving the market growth in the forecast period. However, low quality and inconsistent available data will obstruct the market growth. Also, high cost associated with technology and technical limitations will restrain the market growth.

Data Bridge Market Research analyzes that the Middle East and Africa artificial intelligence (AI) in drug discovery market is expected to reach the value of USD 548.76 million by 2029, at a CAGR of 47.1% during the forecast period. Software accounts for the largest technology segment in the market due to rapid developments in technological advancements to commercialize the use of AI in drug discovery market. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.        

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019-2014)

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

By Application (Novel Drug Candidates, Drug Optimization and Repurposing Preclinical Testing and Approval, Drug Monitoring, Finding New Diseases Associated Targets and Pathways, Understanding Disease Mechanisms, Aggregating and Synthesizing Information, Formation & Qualification of Hypotheses, De Novo Drug Design, Finding Drug Targets of an Old Drug and Others), Technology (Machine Learning, Deep Learning, Natural Language Processing and Others), Drug Type (Small Molecule and Large Molecule), Offering (Software and Services), Indication (Immuno-Oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases and Others), End Use (Contract Research Organizations (CROs), Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes and Others)

Countries Covered

U.A.E, Israel, South Africa, Saudi Arabia, Egypt, rest of Middle East and Africa

Market Players Covered

Some of the key players operating in the market are NVIDIA Corporation, IBM Corp., Atomwise Inc., Microsoft, Benevolent AI, Aria Pharmaceuticals, Inc., DEEP GENOMICS, Exscientia, Cloud, Insilico Medicine, Cyclica, NuMedii, Inc., Envisagenics, Owkin Inc., BERG LLC, Schrödinger, Inc., XtalPi Inc., and BIOAGE Inc. among others

Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market Definition

AI has caught the attention and minds of medical technology practitioners in the past few years, as several companies and major research laboratories have worked to perfect these technologies for clinical use. The first commercialized demonstrations of how AI (also known as Deep Learning (DL), Machine Learning (ML), or Artificial Neural Networks (ANNs)) could assist clinicians are now available. These systems could lead to a paradigm shift in clinician workflow, and increase productivity while simultaneously enhancing treatment and patient throughput. AI for drug discovery is a technology that uses machines to simulate human intelligence to solve complicated challenges in the drug development procedure. The adoption of AI solutions in the clinical trial process eliminates possible obstacles, reduces clinical trial cycle time, and increases the productivity and accuracy of the clinical trial process. Therefore, the adoption of these advanced AI solutions in drug discovery processes is gaining popularity amongst life science industry stakeholders. In the pharmaceutical sector, it aids in the discovery of novel compounds, therapeutic target identification, and the development of customized medications. AI platforms used for drug discovery can prove to be a feasible option for deriving insights into the discovery of drugs to treat and minimize the severity of various chronic diseases.

Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

  • Rise in incidence of chronic diseases propels need for AI in drug discovery

The incidence of chronic diseases is increasing at a rapid pace across the globe. According to the Centers for Disease Control and Prevention (CDC), six in 10 adults in the U.S. have a chronic disease. Furthermore, the CDC also highlights that chronic diseases such as heart disease and diabetes are the leading causes of death in the U.S. Such statistics shed light on the growing prevalence of chronic diseases and the need to bring down the fatality rate caused due to these diseases.

AI platforms used for drug discovery can prove to be a feasible option for deriving insights into the discovery of drugs to treat and minimize the severity of various chronic diseases. Thus, these factors are expected to act as a driver for the market growth during the forecast period.

  • Strategic collaborations, partnerships, and products launch

AI has the potential to transform drug discovery by rapidly accelerating the R&D timeline, making drug development cheaper and faster, and improving the probability of approval. AI can also increase the effectiveness of drug repurposing research.

An increase in cross-industry alliances and collaborations drives the market. Rise in relevance of AI in drug discovery & development, and a surge in funding for R&D activities, including AI technology in the field of drug research, are projected to propel the global market growth. Hence, increase in cross-industry collaborations and partnerships is driving the market.

Restraint

  • High cost associated with technology and technical limitations

The current healthcare sector is facing several complex challenges, such as the increased cost of drugs and therapies, and society needs specific significant changes in this area. The entire success of AI depends on the availability of a substantial amount of data because these data are used for the subsequent training provided to the system. Access to data from various database providers can incur extra costs for a company. Clinical trials are directed towards establishing the safety and efficacy of a drug product in humans for a particular disease condition and require six to seven years along with a substantial financial investment. However, only one out of ten molecules entering these trials gain successful clearance, which is a massive loss for the industry. These failures can result from inappropriate patient selection, shortage of technical requirements, and poor infrastructure. Thus, increasing costs with the technology is acting as a restraint for the market growth.

Opportunity

  • Rise in the investments for R&D

The rise in R&D activities and increasing adoption of cloud-based services and applications will provide beneficial opportunities for market growth.

The industry of AI in biopharma continues to grow after a long period of sepsis. This is reflected in the ongoing flow of investments and increase in the number of collaborations between pharmaceutical corporations and AI companies in 2021 to the previous years. The Biopharma industry’s growth is largely influenced by the active engagement of leading pharmaceutical corporations in AI-related investments. The number of scientific publications in the field of AI in Biopharma, and research collaborations between pharma companies and AI-expertise vendors are rapidly increasing, yet, some pharma corporations are still critical of AI applications. ML and AI applications in the pharmaceutical and healthcare industries lead to the formation of a new interdisciplinary field of data-driven drug discovery in healthcare. Thus, rise in investment in R&D activities is acting as an opportunity for market growth.

Challenge

  • Lack of skilled professionals

The shortage of skilled professionals is expected to hamper the market growth. The employees have to re-train or learn new skill sets to work efficiently on the complex AI machines to get the desired results for the drug. This challenge that prevents full-fledged adoption of AI in the pharmaceutical industry includes the lack of skilled personnel to operate AI-based platforms, limited budget for small organizations, apprehension of replacing humans leading to job loss, skepticism about the data generated by AI, and the black box phenomenon (that is, how the conclusions are reached by the AI platform). The shortage of skills acts as a major hindrance to drug discovery through AI, discouraging companies to adopt AI-based machines for drug discovery.

As skill demands are too high, it has manifested as a challenge to retain and manage skill-specified professionals. Moreover, technological advancement is another aspect that leads to the increased demand for skilled professionals. There is an urgent need for the education of professionals for AI-based technology. Lack of trained and experienced professionals and persistent skill gaps limit the employability prospects and access to quality jobs. It is therefore apparent that the availability of professionals equipped with adequate skills is challenging the market growth.

Post-COVID-19 Impact on Middle East and Africa Artificial Intelligence (AI) In Drug Discovery Market

The COVID-19 outbreak had a beneficial impact on the expansion of AI in drug discovery industry due to its widespread use by various organizations for the identification as well as screening of existing medicines used in the treatment of COVID-19. AI is useful in detecting active chemicals for the prevention of SARS-CoV, HIV, SARS-CoV-2, influenza virus, and others. During the pandemic, economies all over the world relied on AI-based medication discovery rather than traditional vaccine detection processes, which take years to create and are equally expensive, contributing to the growth of the market.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities to improve the technology involved in the Wireless microphone. With this, the companies will bring advanced and accurate AI software to the market.

Recent Developments

  • In March 2022, NVIDIA Corporation launched Clara Holoscan MGX to develop and deploy real-time AI applications. Clara Holoscan MGX expands the Clara Holoscan platform to provide an all-in-one, medical-grade reference architecture, as well as long-term software support, to accelerate innovation in the medical device industry. This will help the company for better AI performance in health sector for surgery, diagnostics, and drug discovery.
  • In May 2022, Benevolent AI, a leading clinical-stage AI-enabled drug discovery company, announced that AstraZeneca has selected an additional novel target for Idiopathic Pulmonary Fibrosis (IPF) for its drug development portfolio, resulting in a milestone payment to Benevolent AI.  This is the third novel target from the collaboration that has been identified using the Benevolent Platform across two disease areas, IPF and chronic kidney disease, and subsequently validated and selected for portfolio entry by AstraZeneca. This builds upon the recent extension of the collaboration with AstraZeneca to include two new disease areas, systemic lupus erythematosus, and heart failure, signed in January 2022. This has helped the company to make its collaboration stronger.

Middle East and Africa Artificial Intelligence (AI) In Drug Discovery Market Scope

Middle East and Africa Artificial Intelligence (AI) in drug discovery market is segmented into application, technology, drug type, offering, indication, and end use. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

 APPLICATION

  • Novel Drug Candidates
  • Drug Optimization and Repurposing Preclinical Testing and Approval
  • Drug Monitoring
  • Finding New Diseases Associated Targets and Pathways
  • Understanding Disease Mechanisms
  • Aggregating and Synthesizing Information
  • Formation & Qualification of Hypotheses
  • De Novo Drug Design
  • Finding Drug Targets of an Old Drug
  • Others

Based on application, the market is segmented into novel drug candidates, drug optimization and repurposing preclinical testing and approval, drug monitoring, finding new diseases associated targets and pathways, understanding disease mechanisms, aggregating and synthesizing information, formation & qualification of hypotheses, de novo drug design, finding drug targets of an old drug, and others.

 TECHNOLOGY

  • Machine Learning (ML)
  • Deep Learning (DL)
  • Natural Language Processing (NLP)
  • Others

Based on technology, the market is segmented into Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), and others.

 DRUG TYPE

  • Small Molecule
  • Large Molecule

Based on drug type, the market is segmented into small molecule and large molecule.

OFFERING

  • Software
  • Services

Based on offering, the market is segmented into software and services.

INDICATION

  • Immuno-Oncology
  • Neurodegenerative Diseases
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Others

Based on indication, the market is segmented into immuno-oncology, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and others.

END USE

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Research Centers and Academic Institutes
  • Others

Artificial Intelligence (AI) in Drug Discovery Market

Based on end use, the market is segmented into pharmaceutical & biotechnology companies, Contract Research Organizations (CROs), research centers and academic institutes, and others.

Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market Regional Analysis/Insights

Middle East and Africa Artificial Intelligence (AI) in drug discovery market is analyzed and market size information is provided by application, technology, drug type, offering, indication, and end use.

The countries covered in this market report are U.A.E, Israel, South Africa, Saudi Arabia, Egypt, rest of Middle East and Africa.

  • In 2022, Middle East and Africa is dominating due to the increase in government funding. South Africa is expected to grow due to rise in R&D activities for AI in drug discovery.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Artificial Intelligence (AI) In Drug Discovery Market Share Analysis

Middle East and Africa Artificial Intelligence (AI) in drug discovery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the Middle East and Africa Artificial Intelligence (AI) in drug discovery market.

Some of the key players operating in the market are NVIDIA Corporation, IBM Corp., Atomwise Inc., Microsoft, Benevolent AI, Aria Pharmaceuticals, Inc., DEEP GENOMICS, Exscientia, Cloud, Insilico Medicine, Cyclica, NuMedii, Inc., Envisagenics, Owkin Inc., BERG LLC, Schrödinger, Inc., XtalPi Inc. and BIOAGE Inc. among others.


SKU-

TABLE 1 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA SERVICES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA DEEP LEARNING IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA NATURAL LANGUAGE PROCESSING (NLP) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA OTHERS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA SMALL MOLECULE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA LARGE MOLECULE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA DRUG OPTIMISATION AND RE-PURPOSING PRE-CLINICAL TESTING AND APPROVAL IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA DRUG MONITORING IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA AGGREGATING AND SYNTHESIZING INFORMATION IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA DE NOVO DRUG DESIGN IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA FINDING DRUG TARGETS OF AN OLD DRUG IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA FORMATION & QUALIFICATION OF HYPOTHESES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA UNDERSTANDING DISEASE MECHANISMS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA FINDING NEW DISEASE-ASSOCIATED TARGETS AND PATHWAYS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA OTHERS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA NEURODEGENERATIVE DISEASES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA METABOLIC DISEASES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA OTHERS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 GLOB MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA CONTRACT RESEARCH ORGANIZATIONS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA RESEARCH CENTRES AND ACADEMIC INSTITUTES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA OTHERS IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA ARTIFICIAL SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA ARTIFICIAL MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA ARTIFICIAL NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA ARTIFICIAL IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)

TABLE 49 SOUTH AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)

TABLE 50 SOUTH AFRICA SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 SOUTH AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 52 SOUTH AFRICA MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 53 SOUTH AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 54 SOUTH AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 55 SOUTH AFRICA NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 56 SOUTH AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 57 SOUTH AFRICA IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 58 SOUTH AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)

TABLE 59 ISRAEL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)

TABLE 60 ISRAEL SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 ISRAEL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 62 ISRAEL MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 63 ISRAEL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 64 ISRAEL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 65 ISRAEL NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 66 ISRAEL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 67 ISRAEL IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 68 ISRAEL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)

TABLE 69 SAUDI ARABIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)

TABLE 70 SAUDI ARABIA SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 71 SAUDI ARABIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 72 SAUDI ARABIA MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 73 SAUDI ARABIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 74 SAUDI ARABIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 75 SAUDI ARABIA NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 76 SAUDI ARABIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 77 SAUDI ARABIA IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 78 SAUDI ARABIA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)

TABLE 79 U.A.E ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)

TABLE 80 U.A.E SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 U.A.E ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 82 U.A.E MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 83 U.A.E ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 84 U.A.E ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 85 U.A.E NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 86 U.A.E ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 87 U.A.E IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 88 U.A.E ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)

TABLE 89 EGYPT ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)

TABLE 90 EGYPT SOFTWARE IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 91 EGYPT ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 92 EGYPT MACHINE LEARNING (ML) IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 93 EGYPT ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 94 EGYPT ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 95 EGYPT NOVEL DRUG CANDIDATES IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 96 EGYPT ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 97 EGYPT IMMUNO-ONCOLOGY IN ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 98 EGYPT ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY END USE, 2020-2029 (USD MILLION)

TABLE 99 REST OF MIDDLE EAST AND AFRICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2029 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market size will be worth USD 548.76 million by 2029.
The Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market growth rate will be 47.1% by 2029.
Rise in incidence of chronic diseases propels need for AI in drug discovery and Strategic collaborations, partnerships, and products launch are the growth drivers of the Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market.
The application, technology, drug type, offering, indication, and end use are the factors on which the Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market research is based.
The major companies in the Middle East and Africa Artificial Intelligence (AI) in Drug Discovery Market are NVIDIA Corporation, IBM Corp., Atomwise Inc., Microsoft, Benevolent AI, Aria Pharmaceuticals, Inc., DEEP GENOMICS, Exscientia, Cloud, Insilico Medicine, Cyclica, NuMedii, Inc., Envisagenics, Owkin Inc., BERG LLC, Schrödinger, Inc., XtalPi Inc. and BIOAGE Inc.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials